Search research articles
Contact Us
Filters
Showing results (321-330 of 703) with videos related to
Page
of 71
Sort By:
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
Nature Communications
|
March 19, 2023
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny H Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Frontiers in Immunology
|
March 27, 2020
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Mehdi R Pirozyan, Helen M McGuire, Abdullah Al Emran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2018
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y Lim, Jenny H Lee, Tuba N Gide, et al.
JAMA Oncology
|
June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials
Georgina V Long, Jeffrey S Weber, James Larkin, et al.
ESMO Open
|
May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C
M Tetzlaff, J M Taube, G V Long, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 20, 2026
GLUT1 expression, lymphocyte distribution and CD3<sup>+</sup> T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Elizabeth C Paver, Tuba N Gide, Zarwa Yaseen, et al.
Cancer Discovery
|
May 17, 2012
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
Hubing Shi, Gatien Moriceau, Xiangju Kong, et al.
British Journal of Cancer
|
June 12, 2014
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
M S Carlino, L E Haydu, H Kakavand, et al.
Page
of 71
Search research articles
Search
Showing results (321-330 of 703) with videos related to
Sort By:
Page
of 71
The New England Journal of Medicine
|
April 27, 2022
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab
Alexander M Menzies, Ines Pires da Silva, Claudia Trojaniello, et al.
Nature Communications
|
March 19, 2023
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny H Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 5, 2023
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, et al.
Frontiers in Immunology
|
March 27, 2020
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Mehdi R Pirozyan, Helen M McGuire, Abdullah Al Emran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2018
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y Lim, Jenny H Lee, Tuba N Gide, et al.
JAMA Oncology
|
June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials
Georgina V Long, Jeffrey S Weber, James Larkin, et al.
ESMO Open
|
May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C
M Tetzlaff, J M Taube, G V Long, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 20, 2026
GLUT1 expression, lymphocyte distribution and CD3<sup>+</sup> T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Elizabeth C Paver, Tuba N Gide, Zarwa Yaseen, et al.
Cancer Discovery
|
May 17, 2012
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
Hubing Shi, Gatien Moriceau, Xiangju Kong, et al.
British Journal of Cancer
|
June 12, 2014
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
M S Carlino, L E Haydu, H Kakavand, et al.
Page
of 71